Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2000-1-27
pubmed:abstractText
Neuropharmacologic agents able to disrupt normal virus-neuron interactions may provide an alternative strategy for the treatment of herpes simplex virus (HSV) infections. We have previously shown that prophylactic treatment with capsaicin, a natural compound that alters function in sensory neurons, can protect guinea pigs against cutaneous HSV disease, even though the compound has no direct antiviral activity. Here we have examined the ability of civamide, the cis isomer of capsaicin, to interfere with HSV disease. We show that, even when the onset of treatment was delayed until after intravaginal virus challenge, primary genital skin disease severity was significantly reduced. In addition, animals treated during primary infection subsequently experienced a long-lasting reduction in recurrent disease. Civamide treatment during latent infection also significantly reduced recurrent disease, although for a shorter period. Further a single weekly treatment with civamide during latent infection was sufficient to reduce recurrent disease, indicating that an infrequent suppressive maintenance therapy might be possible.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-1310837, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-1334128, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-1852779, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-2162021, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-2162369, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-2768576, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-3000982, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-3031173, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-3034759, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-7503497, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-7643884, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-9062368, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-9231875, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-9647450, http://linkedlifedata.com/resource/pubmed/commentcorrection/10543747-9696475
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2685-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Civamide (cis-capsaicin) for treatment of primary or recurrent experimental genital herpes.
pubmed:affiliation
Division of Infectious Diseases, Children's Hospital Medical Center, Cincinnati, Ohio, USA. bourn0@chmcc.org
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.